Ye X, et al. - In this cohort study, investigators assessed aldo-keto reductase family 1 member B10 (AKR1B10), a secretory protein overexpressed in hepatocellular carcinoma (HCC), as a new serum marker for detecting HCC. For this analysis, they consecutively enrolled 1,244 participants from three independent hospitals, including HCC, healthy controls, benign liver tumors, chronic hepatitis B, and liver cirrhosis. Combining AKR1B10 with alpha-fetoprotein (AFP) increases HCC diagnostic accuracy vs AKR1B10 or AFP alone. Findings suggested that AKR1B10 is a new strong serum marker for HCC and early-stage HCC detection and had better diagnostic performance than AFP.